Dawn R Ebach, Traci W Jester, Joseph A Galanko, Ann M Firestine, Rana Ammoury, Jose Cabrera, Julie Bass, Phillip Minar, Kelly Olano, Peter Margolis, Kelly Sandberg, Tiffany M Linnville, Jess Kaplan, Lisa Pitch, Steven J Steiner, Dorsey Bass, Jonathan Moses, Jeremy Adler, Ajay S Gulati, Prateek Wali, Dinesh Pashankar, Anastasia Ivanova, Hans Herfarth, David A Wohl, Keith J Benkov, Jennifer Strople, Jillian Sullivan, Jeanne Tung, Zorela Molle-Rios, Shehzad A Saeed, Athos Bousvaros, Michael D Kappelman
BACKGROUND: Obesity is common among patients with pediatric Crohn's disease (PCD). Some adult studies suggest obese patients respond less well to anti-TNF treatment. This study sought compares anti-TNF response and anti-TNF levels between pediatric patients with normal and high body mass index (BMI). METHODS: The COMBINE trial compared anti-TNF monotherapy to combination therapy with methotrexate in patients with PCD. In this secondary analysis, a comparison of time-to-treatment failure among patients with normal BMI versus BMI Z score > 1, adjusting for prescribed anti-TNF (infliximab or adalimumab), trial treatment assignment (combination versus monotherapy), and relevant covariates...
March 6, 2024: American Journal of Gastroenterology